Cortexyme Inc. [NASDAQ: CRTX] closed the trading session at $30.72 on 02/16/21. The day’s price range saw the stock hit a low of $30.00, while the highest price level was $37.36. The company report on February 16, 2021 that Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer’s Disease.
– Double-blind phase of GAIN Trial to continue as planned, with top-line data expected Q4 2021.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
– Open-Label Extension of atuzaginstat to stop dosing and enrollment.
The stocks have a year to date performance of 10.58 percent and weekly performance of -33.09 percent. The stock has been moved at -31.06 percent over the last six months. The stock has performed -3.73 percent around the most recent 30 days and changed -35.29 percent over the most recent 3-months.
If compared to the average trading volume of 279.22K shares, CRTX reached to a volume of 1436967 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Cortexyme Inc. [CRTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRTX shares is $75.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRTX stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Cortexyme Inc. shares, keeping their opinion on the stock as Sell, with their previous recommendation back on December 11, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on June 24, 2020, representing the official price target for Cortexyme Inc. stock. Previously, the target price had yet another raise to $59, while Jefferies analysts kept a Buy rating on CRTX stock.
The Average True Range (ATR) for Cortexyme Inc. is set at 4.81 The Price to Book ratio for the last quarter was 4.82, with the Price to Cash per share for the same quarter was set at 4.77.
CRTX stock trade performance evaluation
Cortexyme Inc. [CRTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -33.09. With this latest performance, CRTX shares dropped by -3.73% in over the last four-week period, additionally sinking by -31.06% over the last 6 months – not to mention a drop of -57.63% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRTX stock in for the last two-week period is set at 39.23, with the RSI for the last a single of trading hit 33.37, and the three-weeks RSI is set at 42.01 for Cortexyme Inc. [CRTX]. The present Moving Average for the last 50 days of trading for this stock 34.92, while it was recorded at 44.00 for the last single week of trading, and 44.23 for the last 200 days.
Cortexyme Inc. [CRTX]: An insightful look at the core fundamentals
Return on Total Capital for CRTX is now -41.91, given the latest momentum, and Return on Invested Capital for the company is -39.57. Return on Equity for this stock declined to -39.57, with Return on Assets sitting at -37.50.
Reflecting on the efficiency of the workforce at the company, Cortexyme Inc. [CRTX] managed to generate an average of -$1,607,826 per employee.Cortexyme Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.70 and a Current Ratio set at 8.70.
Earnings per share (EPS) analysis for Cortexyme Inc. [CRTX] stock
With the latest financial reports released by the company, Cortexyme Inc. posted -0.35/share EPS, while the average EPS was predicted by analysts to be reported at -0.4/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Cortexyme Inc. go to 18.30%.
Cortexyme Inc. [CRTX]: Insider Ownership positions
There are presently around $536 million, or 57.30% of CRTX stock, in the hands of institutional investors. The top three institutional holders of CRTX stocks are: EPIQ CAPITAL GROUP, LLC with ownership of 3,507,082, which is approximately 2.7% of the company’s market cap and around 0.20% of the total institutional ownership; CAPITAL WORLD INVESTORS, holding 2,610,237 shares of the stock with an approximate value of $80.19 million in CRTX stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $80.05 million in CRTX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Cortexyme Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 49 institutional holders increased their position in Cortexyme Inc. [NASDAQ:CRTX] by around 1,628,648 shares. Additionally, 37 investors decreased positions by around 509,113 shares, while 17 investors held positions by with 15,324,804 shares. The mentioned changes placed institutional holdings at 17,462,565 shares, according to the latest SEC report filing. CRTX stock had 17 new institutional investments in for a total of 240,733 shares, while 18 institutional investors sold positions of 137,202 shares during the same period.